Skip to main content
. 2019 Apr 18;7(4):62. doi: 10.3390/medsci7040062

Figure 2.

Figure 2

Dynamics of the thermal and mechanical withdrawals after HC-030031 pretreatment. Intra-plantar injection of SLIGRL results in a significant decrease of the thermal paw latency (A) and mechanical paw threshold (C), i.e., develops hyperalgesia. However, pretreatment with transient receptor potential ankyrin 1 (TRPA1) antagonist HC-030031 reduces these thermal and mechanical hyperalgesia, respectively. There are weaker mirror hyperalgesic effects for the contralateral paw (B,D). Note, there was a significant difference in the extent of inhibition between 50 mg and 100 mg HC-030031 for 15 mM SLIGRL at 30–60 min of the post-SLIGRL injection (p < 0.001), but not for 40 mM SLIGRL (p > 0.05) in the thermal test (A). The thin black arrow indicates the time of injection of HC-030031 and the bold arrow indicates the time of injection of SLIGRL. BL; pre-injection baseline.